| Variables |
No. of patients |
Mean survival (months) |
14 months PFS proportion (%) |
P value |
| Concurrent methylation status of all three MGMT, TP53 and CDKN2A |
MMM |
6 |
13.20(11.80-14.60) |
80 |
0.131 |
| UUU |
5 |
10.60(6.86-14.34) |
30 |
| Combinations of prognostic analysis of concurrent MGMT:TP53 methylation |
M M |
10 |
11.44(8.75-14.13) |
68.6 |
0.172 |
| U U |
8 |
9.25(5.84-12.66) |
25 |
| Combinations of prognostic analysis of concurrent MGMT:CDKN2A methylation |
M M |
13 |
12.72(11.41-14.04) |
55 |
0.352 |
| U U |
8 |
10.36(7.02-13.73) |
41.7 |
| Combinations of prognostic analysis of concurrent TP53: CDKN2A methylation |
M M |
7 |
11.88(9.22-14.56) |
68.6 |
0.479 |
| U U |
24 |
11.79(10.35-13.24) |
60.2 |
